NVS - 2 Small-Cap Biotechs With Huge Upside
The world of biotech investing can be tricky. And that's particularly true for small-cap stocks in the biotech sector. These companies often have terrific science, but no profits and little if any revenues. And yet there are outstanding opportunities in this sector for investors who know what to look for and have a long-term outlook.
Perhaps the best strategy for healthcare investors looking to add winning biotechs to their portfolio is to invest in a handful of small-cap biotechs. By doing so you diversify your risk. One winning small-cap biotech can more than make up for two or three losses. And investors can stack the odds in their favor by investing in small-cap companies with multiple drugs in their pipelines. Here are two small-cap biotechs that fit the profile: MeiraGTx (NASDAQ: MGTX) and BridgeBio Pharma (NASDAQ: BBIO).
MeiraGTX is a small cap (valued at $678 million) with an ambitious program and six molecules in its pipeline. The company is focused on three distinct forms of genetic disease: ocular, neurodegenerative, and salivary gland.